Regenxbio announces proposed public offering of common stock

8 Aug 2018 The forward-looking statements include statements relating to, among other things, REGENXBIO's proposed offering of its common stock. 12 Feb 2020 The company expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of its common stock (15 percent)  20 Feb 2020 Westport, CT, Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ( Nasdaq: BSGM) (“BioSig” or the “Company”), a medical 

REGENXBIO Announces Proposed Public Offering Of Common Stock /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the The forward-looking statements include statements relating to, among other things, REGENXBIO's proposed offering of its common stock. REGENXBIO has based these forward-looking statements on its Additionally, REGENXBIO has granted the underwriters a 30-day option to purchase an additional 405,000 shares of common stock at the public offering price, less underwriting discounts and commissions. * Regenxbio announces proposed public offering of common stock * Regenxbio Inc says it intends to offer and sell $75 million of its common stock in an underwritten public offering Source text for ROCKVILLE, Md., Aug. 14, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price to the public of $65.00 per share, as well as the exercise in full of the underwriters' option to purchase ROCKVILLE, Md., Aug. 10, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced the pricing of an underwritten public offering of 2,700,000 shares of its common stock at the price of $65.00 per share before underwriting discounts and commissions.

ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $175,000,000

REGENXBIO Announces Proposed Public Offering Of Common Stock 8/8/18 REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. REGENXBIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares By Published: Aug 14, 2018 4:01 p.m. ET REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the pricing of an underwritten public offering of 2,700,000 shares of its common stock at the price of $65.00 per share before underwriting discounts and commissions. ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. REGENXBIO Announces Proposed Public Offering Of $175,000,000 Of Its Common Stock - read this article along with other careers information, tips and advice on BioSpace REGENXBIO Inc. announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. REGENXBIO : Announces Pricing Of Public Offering Of Common Stock ROCKVILLE, Md., Aug. 10, 2018 /PRNewswire/ -- REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy

12 Feb 2020 The company expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of its common stock (15 percent) 

REGENXBIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares By Published: Aug 14, 2018 4:01 p.m. ET REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the pricing of an underwritten public offering of 2,700,000 shares of its common stock at the price of $65.00 per share before underwriting discounts and commissions. ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. REGENXBIO Announces Proposed Public Offering Of $175,000,000 Of Its Common Stock - read this article along with other careers information, tips and advice on BioSpace REGENXBIO Inc. announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. REGENXBIO : Announces Pricing Of Public Offering Of Common Stock ROCKVILLE, Md., Aug. 10, 2018 /PRNewswire/ -- REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy Zogenix also expects to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Zogenix.

Additionally, REGENXBIO has granted the underwriters a 30-day option to purchase an additional 405,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

REGENXBIO Announces Proposed Public Offering Of Common Stock 8/8/18 REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. REGENXBIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares By Published: Aug 14, 2018 4:01 p.m. ET REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the pricing of an underwritten public offering of 2,700,000 shares of its common stock at the price of $65.00 per share before underwriting discounts and commissions. ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. REGENXBIO Announces Proposed Public Offering Of $175,000,000 Of Its Common Stock - read this article along with other careers information, tips and advice on BioSpace REGENXBIO Inc. announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. REGENXBIO : Announces Pricing Of Public Offering Of Common Stock ROCKVILLE, Md., Aug. 10, 2018 /PRNewswire/ -- REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy

REGENXBIO Announces Proposed Public Offering Of $175,000,000 Of Its Common Stock - read this article along with other careers information, tips and advice on BioSpace REGENXBIO Inc. announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering.

ROCKVILLE, Md., Aug. 10, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced the pricing of an underwritten public offering of 2,700,000 shares of its common stock at the price of $65.00 per share before underwriting discounts and commissions. REGENXBIO Announces Proposed Public Offering Of Common Stock - Barron's We've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. The forward-looking statements include statements relating to, among other things, REGENXBIO’s proposed offering of its common stock. REGENXBIO has based these forward-looking statements on its current expectations and assumptions as well as other factors REGENXBIO believes are appropriate under the circumstances. REGENXBIO Announces Proposed Public Offering Of $175,000,000 Of Its Common Stock - read this article along with other careers information, tips and advice on BioSpace REGENXBIO Inc. announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. * Regenxbio announces proposed public offering of common stock * Regenxbio Inc says it intends to offer and sell $75 million of its common stock in an underwritten public offering Source text for REGENXBIO Announces Proposed Public Offering Of Common Stock 8/8/18 REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering.

5 Feb 2020 GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: